Cargando…
Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
Background and aims: There is no established predictive marker for the treatment of renal cancer. Metastatic renal cell carcinoma (mRCC) patients are often treated with sunitinib, a tyrosine kinase inhibitor. Sunitinibs anti-cancer effect is at least partly mediated through interfering with angiogen...
Autores principales: | Niinivirta, Marjut, Enblad, Gunilla, Edqvist, Per-Henrik, Pontén, Fredrik, Dragomir, Anca, Ullenhag, Gustav J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705999/ https://www.ncbi.nlm.nih.gov/pubmed/29187872 http://dx.doi.org/10.7150/jca.20889 |
Ejemplares similares
-
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017) -
Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2019) -
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
por: Niinivirta, Marjut, et al.
Publicado: (2020) -
A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
por: Gremel, Gabriela, et al.
Publicado: (2017) -
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)